Neuron-microglia interaction in neuroinflammation

Current Protein and Peptide Science

Volumn 14, Issue 1, 2013, Pages 16-20

  Suzumura, Akio ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

ALS; CNS; Neurodegenerative disorders; Neuron microglia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CD14 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; CILIARY NEUROTROPHIC FACTOR; CX3C CHEMOKINE; FRACTALKINE; GLUTAMINE; LEUKEMIA INHIBITORY FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIN; PHOSPHATIDYLSERINE; PURINERGIC P2X RECEPTOR; PURINERGIC P2Y RECEPTOR; TRANSFORMING GROWTH FACTOR;

ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; GAP JUNCTION; GENE MUTATION; MICROGLIA; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; CELL COMMUNICATION; CHEMOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MICROGLIA; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPEPTIDES; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 84876701544     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1389203711314010004     Document Type: Article

References (39)

1. D. Farfara; V. Lifshitz; D. Frenkel. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J. Cell Mol. Med., 2008, 12(3), 762-780.
2. S. Honda; Y. Sasaki; K. Ohsawa, et al. Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J. Neurosci., 2001, 21(6), 1975-1982.
3. J. El Khoury and A. D. Luster. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol. Sci., 2008, 29(12), 626-632.
4. F. Bard; C. Cannon; R. Barbour, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6(8), 916-919.
5. J. J. Hoarau; P. Krejbich-Trotot; M. C. Jaffar-Bandjee, et al. Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg), CNS Neurol. Disord. Drug Targets, 2011, 10(1), 25-43.
6. A. D. Fuller and L. J. Van Eldik. MFG-E8 regulates microglial phagocytosis of apoptotic neurons. J. Neuroimmune. Pharmacol., 2008, 3(4), 246-256
7. S. McArthur; E. Cristante; M. Paterno, et al. Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia. J. Immunol., 2010, 185(10), 6317-6328.
8. G. R. Sambrano and D. Steinberg. Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine. Proc. Natl. Acad. Sci. USA., 1995, 92(5), 1396-1400.
9. R. J. Horvath and J. A. DeLeo. Morphine enhances microglial migration through modulation of P2X4 receptor signaling. J. Neurosci., 2009, 29(4), 998-1005.
10. Y. Liu; S. Walter; M. Stagi, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain, 2005, 128(8), 1778-1789.
11. A. Stolzing and T. Grune. Neuronal apoptotic bodies: phagocytosis and degradation by primary microglial cells. Faseb J., 2004, 18(6), 743-745.
12. G. E. Landreth and E. G. Reed-Geaghan. Toll-like receptors in Alzheimer's disease. Curr. Top Microbiol. Immunol., 2009, 336, 137-153.
13. A. E. Cardona; E. P. Pioro; M. E. Sasse, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci., 2006, 9(7), 917-924.
14. S. Lee; N. H. Varvel; M. E. Konerth, et al. CX3CR1 deficiency alters microglial activation and reduces β-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol., 2010, 177(5), 2549-2562.
15. T. Mizuno; Y. Doi; H. Mizoguchi, et al. Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-beta neurotoxicity. Am. J. Pathol., 2011, 179(4), 2016-2027.
16. T. Mizuno; G. Zhang; H. Takeuchi, et al. Interferon-gamma directly induces neurotoxicity through a neuron specific, calciumpermeable complex of IFN-gamma and AMPA GluR1 receptor. FASEB J., 2008, 22(6), 1797-1806.
17. H. Takeuchi; T. Mizuno; G. Zhang, et al. Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal Tansport. J. Biol. Chem., 2005, 280(11), 10444-10454.
18. H. Takeuchi; J. Wnag; J. Kawanokuchi, et al. Tumor necrosis factoralpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in autocrine manner. J. Biol. Chem., 2006, 281(30), 21362-21368.
19. H. Takeuchi; H. Mizoguchi; Y. Doi, et al. Blockade of gap junction hemichanel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS One, 2011, 6(6), e21108.
20. PB. Tran and Miller, R. J. Chemokine receptors in the brain: a developing story. Nat. Rev. Neurosci., 2003, 4(6), 444-455.
21. Y. Pan; C. Lloyd; H. Zhou, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature, 1997, 387(6633), 611-617.
22. T. Mizuno; J. Kawanokuchi; K. Numata, et al. Production and neuroprotective functions of flactalkine in the central nervous system. Brain Res., 2003, 979(1-2), 65-70.
23. C. Limatola; C. Lauro; M. Catalano, et al. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J. Neuroimmunol., 2005, 166 (1-2), 19-28.
24. M. Miksa; D. Amin; R. Wu, et al. Fractalkine-induced MFG-E8 leads o enhanced apoptotic cell clearance by macrophages. Mol. Med., 2007, 13(11-12), 553-560.
25. Y. Pan; C. Lloyd; H. Zhou, et al. Neurotactin, a membraneanchored chemokine upregulated in brain inflammation. Nature, 1997, 387(6633), 611-617.
26. A. Nishiyori; M. Minami; Y. Ohtani, et al. Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett., 1998, 429(2), 167-172.
27. J. K. Harrison; Y. Jiang; S. Chen, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. USA., 1998, 95(18), 10896-10901.
28. K. Hatori; A. Nagai; R. Heisel, et al. Fractalkine and fractalkine receptors in human neurons and glial cells. J. Neurosci. Res., 2002, 69(3), 418-426.
29. S. A. Boehme; F. M. Lio; D. Maciejewski-Lenoir, et al. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J. Immunol., 2000, 165(1), 397-403.
30. C. Lauro; S. Di Angelantonio; R. Cipriani, et al. Activity of adenosine receptors type 1 Is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons. J. Immunol., 2008, 180(11), 7590-7596.
31. M. Noda; Y. Doi; J. Liang, et al. Fractalkine attenuates excitoneurotoxicity via microglial clearance of damaged neurons and antioxidant enzyme heme oxygenase-1 expression. J. Biol. Chem., 2011, 286(3), 2308-2319.
32. V. Zujovic; J. Benavides, X. Vige, et al. Fractalkine modulates TNF-α secretion and neurotoxicity induced by microglial activation. Glia, 2000, 29(4), 305-315.
33. K. J. Garton; P. J. Gough; C. P. Blobel, et al. Tumor necrosis factor- α-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem., 2001, 276(41), 37993-38001.
34. C. Hundhausen; D. Misztela; T. A. Berkhout, et al. The disintegrinlike metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cellcell adhesion. Blood, 2003, 102(4), 1186-1195.
35. C. L. Tsou; C. A. Haskell and I. F. Charo. Tumor necrosis factor-α- converting enzyme mediates the inducible cleavage of fractalkine. J. Biol. Chem., 2001, 276(48), 44622-44626.
36. A. K. Clark; P. K. Yip; J. Grist, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc. Natl. Acad. Sci. USA., 2007, 104(25), 10655-10660.
37. S. R. Green; K. H. Han; Y. Chen, et al. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. J. Immunol., 2006, 176(12), 7412-7420.
38. M. M. Pabon; A. D. Bachstetter; C. E. Hudson, et al. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J. Neuroinflamm., 2011, 8, 9.
39. M. Fuhrmann; T. Bittner; C. K. Jung, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci., 2010, 13(4), 411-413.